Accropeutics Secured $12 Million in Series B Plus Financing

Whats Happening:

Accropeutics, a clinical-stage biotechnology company, has secured $12 million in Series B Plus financing. The round was led by Shenzhen Capital Group (SCGC), with participation from existing investor Morningside Ventures and new investors Leader Venture Investment (SZTI) and Hefei Sci-Tec Venture Capital (HFST). This funding extends the company's cash runway into the second half of 2026.

Key Moves:

• Accropeutics raises $12 million in Series B Plus financing

• Funding led by Shenzhen Capital Group with participation from existing and new investors

• Cash runway extended into the second half of 2026

By The Numbers:

• $12 million raised in Series B Plus financing

• Cash runway extended into second half of 2026

• 23 issued patents in China, Japan, Korea, US and the EU

Key Quotes:

• "With this round of financing, we are able to continue advancing our lead programs and solidify our position as an innovative, multi-program, clinical-stage biotech company," said Dr. Xiaohu (Jason) Zhang, Co-founder and CEO of Accropeutics.

• "I am grateful to our existing and new investors, who share our vision that we can transform the treatment landscape for a wide range of I&I diseases with potentially best-in-class therapies."

Bottom Line:

Accropeutics' successful $12 million Series B Plus financing strengthens its position in developing novel therapeutics for immune-mediated diseases. The funding will support ongoing clinical trials and advance the company's pipeline, potentially transforming treatment options for patients with conditions like Ulcerative Colitis, Psoriasis, and acute Graft-versus-Host Disease.

Read Full Article